Rasagilina (Portuguese Wikipedia)

Analysis of information sources in references of the Wikipedia article "Rasagilina" in Portuguese language version.

refsWebsite

Global rank Portuguese rank

14nih.gov

4^th place

8^th place

13worldcat.org

5^th place

5doi.org

2^nd place

4^th place

2pharmamedtechbi.com

low place

2fda.gov

447^th place

869^th place

1docs.google.com

1,047^th place

581^st place

1jpost.com

544^th place

911^th place

1eisai.com

low place

1haaretz.com

497^th place

733^rd place

docs.google.com

US 3,513,244. See US patent 5453446, lines 50-60. US Patent 5453446 was the patent at issue in Teva v Watson, see page 2

doi.org

dx.doi.org

Lakhan, Shaheen E. (1 de janeiro de 2007). «From a Parkinson's disease expert: Rasagiline and the future of therapy». Molecular Neurodegeneration. 2. 13 páginas. ISSN 1750-1326. PMID 17617893. doi:10.1186/1750-1326-2-13
Stocchi, Fabrizio; Chiara (1 de janeiro de 2015). «Rasagiline for the treatment of Parkinson's disease: an update». Expert Opinion on Pharmacotherapy. 16 (14): 2231–2241. ISSN 1744-7666. PMID 26364897. doi:10.1517/14656566.2015.1086748
Poewe, Werner; Philipp (15 de setembro de 2015). «Therapeutic advances in multiple system atrophy and progressive supranuclear palsy». Movement Disorders: Official Journal of the Movement Disorder Society. 30 (11): 1528–1538. ISSN 1531-8257. PMID 26227071. doi:10.1002/mds.26334
Chen, Jack J.; David M. (1 de agosto de 2005). «Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease». Journal of Clinical Pharmacology. 45 (8): 878–894. ISSN 0091-2700. PMID 16027398. doi:10.1177/0091270005277935
Schapira, Anthony; Guy (1 de agosto de 2005). «Rasagiline». Nature Reviews. Drug Discovery. 4 (8): 625–626. ISSN 1474-1776. PMID 16106586. doi:10.1038/nrd1803

eisai.com

Eisai Press Release. May 15, 2003

fda.gov

accessdata.fda.gov

Azilect Prescribing Information Label last revised May, 2014

fda.gov

Russel Katz, M.D.; et al. "Peripheral and Central Nervous System Advisory Committee Background Package on Azilect" (PDF). FDA. Retrieved December 7,2011.

haaretz.com

Vadim Sviderski for Reuters and Haaretz. Oct 19, 2011FDA Advisers Refuse Teva Plea to Expand Azilect Label

jpost.com

Judy Sielg-Itzkovich for the Jerusalem Post. November 13, 2010. Making armor for the brain

nih.gov

ncbi.nlm.nih.gov

Akao, Yukihiro; Wakako (28 de junho de 2002). «An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells». Neuroscience Letters. 326 (2): 105–108. ISSN 0304-3940. PMID 12057839
Oldfield, Vicki; Gillian M. (1 de janeiro de 2007). «Rasagiline: a review of its use in the management of Parkinson's disease». Drugs. 67 (12): 1725–1747. ISSN 0012-6667. PMID 17683172
Gallagher, David A.; Anette (1 de janeiro de 2008). «Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease». CNS drugs. 22 (7): 563–586. ISSN 1172-7047. PMID 18547126
Lakhan, Shaheen E. (1 de janeiro de 2007). «From a Parkinson's disease expert: Rasagiline and the future of therapy». Molecular Neurodegeneration. 2. 13 páginas. ISSN 1750-1326. PMID 17617893. doi:10.1186/1750-1326-2-13
Stocchi, Fabrizio; Chiara (1 de janeiro de 2015). «Rasagiline for the treatment of Parkinson's disease: an update». Expert Opinion on Pharmacotherapy. 16 (14): 2231–2241. ISSN 1744-7666. PMID 26364897. doi:10.1517/14656566.2015.1086748
Poewe, Werner; Philipp (15 de setembro de 2015). «Therapeutic advances in multiple system atrophy and progressive supranuclear palsy». Movement Disorders: Official Journal of the Movement Disorder Society. 30 (11): 1528–1538. ISSN 1531-8257. PMID 26227071. doi:10.1002/mds.26334
Stark, Charles R. (1 de setembro de 1932). «Hospital Costs Stagger Nation». California and Western Medicine. 37 (3): 214–215. ISSN 0093-4038. PMID 18742268
Bar Am, Orit; Tamar (30 de janeiro de 2004). «Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline». Neuroscience Letters. 355 (3): 169–172. ISSN 0304-3940. PMID 14732458
Yasar, S.; Goldberg, J. P.; Goldberg, S. R. (1996-01-01). "Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research".Journal of Neural Transmission. Supplementum 48: 61–73. ISSN 0303-6995.PMID 8988462.
Chen, Jack J.; David M. (1 de agosto de 2005). «Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease». Journal of Clinical Pharmacology. 45 (8): 878–894. ISSN 0091-2700. PMID 16027398. doi:10.1177/0091270005277935
Schapira, Anthony; Guy (1 de agosto de 2005). «Rasagiline». Nature Reviews. Drug Discovery. 4 (8): 625–626. ISSN 1474-1776. PMID 16106586. doi:10.1038/nrd1803
Lecht, Shimon; Simon (1 de junho de 2007). «Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy». Therapeutics and Clinical Risk Management. 3 (3): 467–474. ISSN 1176-6336. PMID 18488080
Finberg JP, Lamensdorf I, Commissiong JW, Youdim MB. Pharmacology and neuroprotective properties of rasagiline. Pharmacology and neuroprotective properties of rasagiline. J Neural Transm Suppl. 1996;48:95-101.PMID 8988465
Kupsch, Andreas (1 de maio de 2002). «Rasagiline. Teva Pharmaceutical». Current Opinion in Investigational Drugs (London, England: 2000). 3 (5): 794–797. ISSN 1472-4472. PMID 12090555

pharmamedtechbi.com

US 3,513,244. See US patent 5453446, lines 50-60. US Patent 5453446 was the patent at issue in Teva v Watson, see page 2
Teva v Watson, see page 2

worldcat.org

Akao, Yukihiro; Wakako (28 de junho de 2002). «An anti-Parkinson's disease drug, N-propargyl-1(R)-aminoindan (rasagiline), enhances expression of anti-apoptotic bcl-2 in human dopaminergic SH-SY5Y cells». Neuroscience Letters. 326 (2): 105–108. ISSN 0304-3940. PMID 12057839
Oldfield, Vicki; Gillian M. (1 de janeiro de 2007). «Rasagiline: a review of its use in the management of Parkinson's disease». Drugs. 67 (12): 1725–1747. ISSN 0012-6667. PMID 17683172
Gallagher, David A.; Anette (1 de janeiro de 2008). «Impact of newer pharmacological treatments on quality of life in patients with Parkinson's disease». CNS drugs. 22 (7): 563–586. ISSN 1172-7047. PMID 18547126
Lakhan, Shaheen E. (1 de janeiro de 2007). «From a Parkinson's disease expert: Rasagiline and the future of therapy». Molecular Neurodegeneration. 2. 13 páginas. ISSN 1750-1326. PMID 17617893. doi:10.1186/1750-1326-2-13
Stocchi, Fabrizio; Chiara (1 de janeiro de 2015). «Rasagiline for the treatment of Parkinson's disease: an update». Expert Opinion on Pharmacotherapy. 16 (14): 2231–2241. ISSN 1744-7666. PMID 26364897. doi:10.1517/14656566.2015.1086748
Poewe, Werner; Philipp (15 de setembro de 2015). «Therapeutic advances in multiple system atrophy and progressive supranuclear palsy». Movement Disorders: Official Journal of the Movement Disorder Society. 30 (11): 1528–1538. ISSN 1531-8257. PMID 26227071. doi:10.1002/mds.26334
Stark, Charles R. (1 de setembro de 1932). «Hospital Costs Stagger Nation». California and Western Medicine. 37 (3): 214–215. ISSN 0093-4038. PMID 18742268
Bar Am, Orit; Tamar (30 de janeiro de 2004). «Contrasting neuroprotective and neurotoxic actions of respective metabolites of anti-Parkinson drugs rasagiline and selegiline». Neuroscience Letters. 355 (3): 169–172. ISSN 0304-3940. PMID 14732458
Yasar, S.; Goldberg, J. P.; Goldberg, S. R. (1996-01-01). "Are metabolites of l-deprenyl (selegiline) useful or harmful? Indications from preclinical research".Journal of Neural Transmission. Supplementum 48: 61–73. ISSN 0303-6995.PMID 8988462.
Chen, Jack J.; David M. (1 de agosto de 2005). «Clinical pharmacology of rasagiline: a novel, second-generation propargylamine for the treatment of Parkinson disease». Journal of Clinical Pharmacology. 45 (8): 878–894. ISSN 0091-2700. PMID 16027398. doi:10.1177/0091270005277935
Schapira, Anthony; Guy (1 de agosto de 2005). «Rasagiline». Nature Reviews. Drug Discovery. 4 (8): 625–626. ISSN 1474-1776. PMID 16106586. doi:10.1038/nrd1803
Lecht, Shimon; Simon (1 de junho de 2007). «Rasagiline - a novel MAO B inhibitor in Parkinson's disease therapy». Therapeutics and Clinical Risk Management. 3 (3): 467–474. ISSN 1176-6336. PMID 18488080
Kupsch, Andreas (1 de maio de 2002). «Rasagiline. Teva Pharmaceutical». Current Opinion in Investigational Drugs (London, England: 2000). 3 (5): 794–797. ISSN 1472-4472. PMID 12090555